Combination Therapy for Pancreatic Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a combination of therapies in patients with advanced pancreatic cancer. The treatment aims to kill cancer cells directly, boost the immune system, and stop cancer growth. It focuses on patients whose cancer has spread and may not respond to standard treatments.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, you cannot take certain medications like strong CYP3A4 inhibitors or inducers, and you should avoid live vaccines and systemic immunosuppressive medications before and during the trial.
What safety data exists for the combination therapy involving Anetumab Ravtansine, Gemcitabine, Ipilimumab, and Nivolumab?
Gemcitabine, when combined with other drugs like nab-paclitaxel, erlotinib, and capecitabine, has shown an acceptable safety profile in patients with advanced pancreatic cancer. Nivolumab combined with nab-paclitaxel and gemcitabine was also assessed for safety in advanced pancreatic cancer, indicating it is generally safe for human use.12345
How is the combination therapy for pancreatic cancer with Anetumab Ravtansine, Gemcitabine Hydrochloride, Ipilimumab, and Nivolumab different from other treatments?
This combination therapy is unique because it includes a mix of chemotherapy (Gemcitabine), targeted therapy (Anetumab Ravtansine), and immunotherapy (Ipilimumab and Nivolumab), which is not a standard approach for pancreatic cancer. While Gemcitabine is a common treatment, the addition of these other drugs aims to enhance the immune response and target cancer cells more effectively, offering a novel strategy compared to traditional chemotherapy alone.26789
What data supports the effectiveness of the drug combination therapy for pancreatic cancer?
Research shows that combining ipilimumab (an immune therapy) with gemcitabine (a chemotherapy drug) may help overcome resistance in pancreatic cancer, potentially improving treatment outcomes. Additionally, gemcitabine combined with other drugs like nab-paclitaxel has been shown to improve survival in patients with advanced pancreatic cancer compared to using gemcitabine alone.1011121314
Who Is on the Research Team?
Anna Spreafico, MD PhD
Principal Investigator
University Health Network Princess Margaret Cancer Center LAO
Are You a Good Fit for This Trial?
This trial is for adults with advanced pancreatic cancer that has spread and can't be removed by surgery. Participants must have tried at least one treatment before, have tumors expressing a protein called mesothelin, and be in good physical condition (ECOG score 0-1). They should not have untreated brain metastases or certain infections like HIV or hepatitis B/C. Women who can bear children and men with partners of childbearing potential must use effective contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive anetumab ravtansine with nivolumab, ipilimumab, or gemcitabine in cycles of 21 or 28 days for up to 17 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Anetumab Ravtansine
- Gemcitabine Hydrochloride
- Ipilimumab
- Nivolumab
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor